Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition
- 22 April 2005
- journal article
- review article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 9 (2), 267-281
- https://doi.org/10.1517/14728222.9.2.267
Abstract
Metabolic syndrome is defined as a clustering of cardiovascular risk factors (abdominal obesity, hyperinsulinaemia, atherogenic dislipidaemia, hypertension, hypercoagulability) that together increase the risk of developing coronary heart disease and Type-2 diabetes. Inhibition of acetyl-CoA carboxylase (ACC), with its resultant inhibition of fatty acid synthesis and stimulation of fatty acid oxidation, has the potential to favourably affect, in a concerted manner, a multitude of cardiovascular risk factors associated with metabolic syndrome. Studies in ACC2 knockout mice and in experimental animals treated with isozyme-nonselective ACC inhibitors have demonstrated the potential for treating metabolic syndrome through this modality. A variety of structurally diverse, mechanistically distinct classes of ACC inhibitors have been disclosed in the scientific and patent literature. Isozyme-nonselective ACC inhibitors may provide the optimal therapeutic potential for beneficially affecting metabolic syndrome. However, demonstration of the full potential of isozyme-selective inhibitors, once identified, should reveal advantages and liabilities associated with single isozyme inhibition. Whereas demonstrating clinical efficacy of an ACC inhibitor should be straightforward, the heterogeneity of the patient population and absence of established guidelines regarding approval end points for agents simultaneously affecting multiple aspects of metabolic syndrome will pose developmental challenges for initial market entries.Keywords
This publication has 71 references indexed in Scilit:
- Definition of Metabolic SyndromeCirculation, 2004
- Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severityThe American Journal of Cardiology, 2004
- Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistanceJournal of Internal Medicine, 2003
- Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal MenJournal of Clinical Endocrinology & Metabolism, 2002
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- New drug targets for type 2 diabetes and the metabolic syndromeNature, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Cardiovascular Morbidity and Mortality Associated With the Metabolic SyndromeDiabetes Care, 2001
- Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X)Diabetes, 1992
- Role of Insulin Resistance in Human DiseaseDiabetes, 1988